(ANSAmed) - TEL AVIV, AUGUST 13 - The three former patients, who at the beginning of this week were administered the drug created with the antibodies found in the plasma that had been cured of the infection, were ill in non-serious conditions with pneumonia induced by Covid 19. The trial began last Thursday and involved 12 patients - the media reported - divided into groups. The first was 3 patients, the last of whom was discharged yesterday. According to doctors, patients are in good enough conditions to stay at home but still need to be tested if they are negative for the virus. "I do not know if it is the luck of beginners - added Rothstein who is still cautious about the matter - but we are very excited. For a doctor to see such an improvement in such a short period of time it is surprising". Positive comments also from Kamada, a company among the first in the world - they have media reminders - to focus on a drug derived from antibodies.
"We used - explained Amir London, CEO of Kamada, quoted by Times of Israel - convalescent plasma as a raw material, but then subjected to pharmaceutical treatment and processed to become a drug. When using an infusion (of anticorpiregolari, ed) we do not know exactly what you are giving ". Instead, with the drug developed, they ensure - he continued - predefined and standardized quantities of antibodies and patients are given "a viral treatment that can reduce viral load". The product - he added, still quoted from the same source - is "a hyperimmune globulin, sometimes defined as a passive vaccine. Called this way because unlike a regular vaccine" which induces the body to create antibodies to fight viruses or bacteria, it contains preformed antibodies " . London - also cautious of the first encouraging successes - said that the choice of experimenting on patients in moderate conditions, suffering from Covid 19 pneumonia, but not yet ventilated, is linked to the fact that "they wanted to take them when they are still highly vital and before deterioration, in order to treat this viral phase with an antiviral remedy ". (ANSAmed) (ANSA).
Coronavirus: Israel, success for the antibody drug
2020-08-13T15:37:04.800Z
The three former patients, who at the beginning of this week were given the drug created with the antibodies found in the plasma of recovered from the infection, were ill in non-serious conditions with pneumonia induced by Covid 19. (ANSA)